Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 23 | 2016 | 191 | 3.500 |
Why?
|
| Middle Cerebral Artery | 15 | 2013 | 110 | 3.140 |
Why?
|
| Endothelium, Vascular | 20 | 2013 | 514 | 2.830 |
Why?
|
| Cerebral Arteries | 15 | 2016 | 79 | 2.590 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 8 | 2014 | 32 | 2.500 |
Why?
|
| Cerebrovascular Circulation | 19 | 2014 | 434 | 2.460 |
Why?
|
| Muscle, Smooth, Vascular | 16 | 2011 | 239 | 2.220 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2023 | 203 | 1.670 |
Why?
|
| Rats | 43 | 2023 | 3653 | 1.460 |
Why?
|
| Vasoconstriction | 13 | 2014 | 104 | 1.430 |
Why?
|
| Rats, Long-Evans | 25 | 2016 | 103 | 1.430 |
Why?
|
| Nitric Oxide | 13 | 2013 | 439 | 1.380 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2023 | 679 | 1.380 |
Why?
|
| Blood Pressure | 10 | 2022 | 1325 | 1.090 |
Why?
|
| Cerebral Cortex | 8 | 2012 | 448 | 1.050 |
Why?
|
| Biological Factors | 6 | 2013 | 28 | 1.030 |
Why?
|
| Sleep | 3 | 2015 | 345 | 0.900 |
Why?
|
| Adenosine Triphosphate | 6 | 2013 | 287 | 0.830 |
Why?
|
| Arterioles | 7 | 2012 | 28 | 0.770 |
Why?
|
| Hypertension | 5 | 2023 | 1286 | 0.770 |
Why?
|
| Brain | 7 | 2019 | 2961 | 0.760 |
Why?
|
| Animals | 55 | 2023 | 33793 | 0.730 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 141 | 0.690 |
Why?
|
| Brain Injuries | 5 | 2010 | 762 | 0.680 |
Why?
|
| NG-Nitroarginine Methyl Ester | 13 | 2013 | 59 | 0.640 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 4285 | 0.590 |
Why?
|
| Dysbiosis | 3 | 2023 | 118 | 0.570 |
Why?
|
| Potassium | 3 | 2010 | 279 | 0.570 |
Why?
|
| Cyclic GMP | 3 | 2009 | 92 | 0.540 |
Why?
|
| Vasodilator Agents | 4 | 2013 | 203 | 0.540 |
Why?
|
| Arachidonic Acid | 5 | 2010 | 70 | 0.540 |
Why?
|
| Receptors, Purinergic P2 | 4 | 1999 | 18 | 0.530 |
Why?
|
| Period Circadian Proteins | 1 | 2016 | 28 | 0.520 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.510 |
Why?
|
| In Vitro Techniques | 12 | 2006 | 966 | 0.500 |
Why?
|
| Stroke | 2 | 2022 | 956 | 0.490 |
Why?
|
| Circadian Clocks | 1 | 2016 | 59 | 0.490 |
Why?
|
| Receptors, Endothelin | 1 | 2014 | 9 | 0.480 |
Why?
|
| Wounds, Nonpenetrating | 3 | 2003 | 209 | 0.480 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 74 | 0.480 |
Why?
|
| Phospholipases A | 2 | 2006 | 39 | 0.480 |
Why?
|
| Endothelin-1 | 1 | 2014 | 39 | 0.480 |
Why?
|
| Basilar Artery | 2 | 2010 | 25 | 0.480 |
Why?
|
| Membrane Potentials | 3 | 2011 | 304 | 0.460 |
Why?
|
| Potassium Channels | 6 | 2006 | 158 | 0.450 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 269 | 0.440 |
Why?
|
| Purinergic P2Y Receptor Agonists | 1 | 2013 | 5 | 0.440 |
Why?
|
| White Matter | 1 | 2015 | 181 | 0.420 |
Why?
|
| Potassium Chloride | 5 | 2011 | 54 | 0.390 |
Why?
|
| Arginine | 5 | 2005 | 303 | 0.380 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2010 | 11 | 0.370 |
Why?
|
| Male | 41 | 2023 | 60086 | 0.360 |
Why?
|
| Aorta | 2 | 2011 | 542 | 0.360 |
Why?
|
| Rats, Inbred WKY | 3 | 2022 | 54 | 0.360 |
Why?
|
| Rats, Inbred SHR | 3 | 2022 | 64 | 0.360 |
Why?
|
| Hypothalamus | 1 | 2012 | 217 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2013 | 1682 | 0.350 |
Why?
|
| Calcium | 6 | 2006 | 1095 | 0.340 |
Why?
|
| Vasomotor System | 3 | 2006 | 25 | 0.340 |
Why?
|
| Penicillamine | 4 | 2002 | 6 | 0.330 |
Why?
|
| Enzyme Inhibitors | 9 | 2005 | 571 | 0.330 |
Why?
|
| Neuroprotective Agents | 1 | 2010 | 150 | 0.320 |
Why?
|
| Aorta, Thoracic | 2 | 2013 | 520 | 0.320 |
Why?
|
| Carbon Dioxide | 2 | 2000 | 273 | 0.310 |
Why?
|
| Indomethacin | 5 | 2013 | 84 | 0.310 |
Why?
|
| TRPV Cation Channels | 1 | 2006 | 34 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2013 | 220 | 0.270 |
Why?
|
| Aminolevulinic Acid | 1 | 2006 | 9 | 0.260 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2006 | 12 | 0.260 |
Why?
|
| Brain Ischemia | 2 | 1999 | 258 | 0.260 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 27 | 0.260 |
Why?
|
| Epoprostenol | 1 | 2005 | 67 | 0.240 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 113 | 0.240 |
Why?
|
| Glyburide | 3 | 2000 | 22 | 0.240 |
Why?
|
| Hypoglycemia | 2 | 1998 | 191 | 0.230 |
Why?
|
| Nitric Oxide Synthase | 6 | 2001 | 186 | 0.230 |
Why?
|
| Potassium Channel Blockers | 4 | 2010 | 84 | 0.220 |
Why?
|
| Signal Transduction | 2 | 2014 | 4490 | 0.220 |
Why?
|
| Mice, Knockout | 4 | 2013 | 3720 | 0.220 |
Why?
|
| Vascular Resistance | 1 | 2003 | 189 | 0.200 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 1998 | 34 | 0.190 |
Why?
|
| Muscle Contraction | 2 | 2000 | 186 | 0.180 |
Why?
|
| Neuropeptide Y | 1 | 2001 | 36 | 0.180 |
Why?
|
| Blotting, Western | 3 | 2014 | 1100 | 0.180 |
Why?
|
| Ileum | 1 | 2021 | 132 | 0.180 |
Why?
|
| Environment | 1 | 2021 | 142 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 2 | 2011 | 137 | 0.170 |
Why?
|
| Uridine Triphosphate | 4 | 2002 | 11 | 0.170 |
Why?
|
| Nitric Oxide Donors | 2 | 2013 | 23 | 0.160 |
Why?
|
| Reperfusion | 1 | 1998 | 25 | 0.150 |
Why?
|
| Mice | 8 | 2014 | 17540 | 0.150 |
Why?
|
| Quinoxalines | 4 | 2002 | 39 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 1999 | 102 | 0.150 |
Why?
|
| Homeostasis | 2 | 1999 | 682 | 0.150 |
Why?
|
| Hypotension | 1 | 1999 | 177 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 1999 | 426 | 0.150 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 58 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1687 | 0.140 |
Why?
|
| Intracranial Pressure | 4 | 1999 | 182 | 0.140 |
Why?
|
| Rats, Inbred Strains | 4 | 1998 | 229 | 0.140 |
Why?
|
| Charybdotoxin | 3 | 2001 | 8 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1996 | 5 | 0.140 |
Why?
|
| Polyamines | 1 | 1996 | 26 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 810 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1995 | 8 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 510 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 117 | 0.120 |
Why?
|
| Phospholipases A2 | 2 | 2006 | 35 | 0.120 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2010 | 56 | 0.120 |
Why?
|
| Cricetinae | 2 | 2009 | 410 | 0.120 |
Why?
|
| Femoral Artery | 1 | 1996 | 190 | 0.120 |
Why?
|
| Polysomnography | 1 | 2015 | 140 | 0.120 |
Why?
|
| Barium Compounds | 3 | 1999 | 6 | 0.120 |
Why?
|
| Receptors, Purinergic P2Y2 | 3 | 1999 | 17 | 0.120 |
Why?
|
| Gene Expression | 2 | 2009 | 1566 | 0.120 |
Why?
|
| Chlorides | 3 | 1999 | 104 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 62 | 0.110 |
Why?
|
| Catecholamines | 1 | 1994 | 58 | 0.110 |
Why?
|
| Blood Glucose | 1 | 1998 | 1119 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 5 | 2014 | 4356 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 63 | 0.110 |
Why?
|
| Calcimycin | 1 | 2013 | 26 | 0.110 |
Why?
|
| Phenylephrine | 1 | 2013 | 37 | 0.110 |
Why?
|
| Respiration | 1 | 2013 | 122 | 0.100 |
Why?
|
| Hyperoxia | 1 | 2014 | 127 | 0.100 |
Why?
|
| Superoxide Dismutase | 3 | 2005 | 139 | 0.100 |
Why?
|
| Pia Mater | 2 | 2003 | 10 | 0.100 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2011 | 6 | 0.100 |
Why?
|
| Calcium Channel Agonists | 1 | 2011 | 12 | 0.100 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2011 | 39 | 0.100 |
Why?
|
| Trachea | 1 | 2013 | 201 | 0.100 |
Why?
|
| Fura-2 | 2 | 2001 | 12 | 0.100 |
Why?
|
| Time Factors | 3 | 2013 | 6222 | 0.090 |
Why?
|
| rho-Associated Kinases | 1 | 2011 | 55 | 0.090 |
Why?
|
| S-Nitroso-N-Acetylpenicillamine | 2 | 2001 | 2 | 0.090 |
Why?
|
| Catalase | 2 | 2001 | 50 | 0.090 |
Why?
|
| Free Radical Scavengers | 2 | 2001 | 49 | 0.090 |
Why?
|
| Hypercapnia | 2 | 2001 | 20 | 0.090 |
Why?
|
| Stress, Mechanical | 2 | 2001 | 170 | 0.090 |
Why?
|
| Oxadiazoles | 2 | 2002 | 25 | 0.090 |
Why?
|
| Thionucleotides | 2 | 2002 | 19 | 0.090 |
Why?
|
| alpha-Linolenic Acid | 1 | 2010 | 15 | 0.090 |
Why?
|
| Cell Count | 1 | 2010 | 250 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 213 | 0.090 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 23 | 0.090 |
Why?
|
| Barium | 1 | 2009 | 17 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 88 | 0.080 |
Why?
|
| Cricetulus | 1 | 2009 | 97 | 0.080 |
Why?
|
| Fluorescent Dyes | 2 | 2001 | 260 | 0.080 |
Why?
|
| CHO Cells | 1 | 2009 | 157 | 0.080 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Glucose | 1 | 1994 | 872 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 160 | 0.080 |
Why?
|
| Electroencephalography | 1 | 1994 | 860 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1161 | 0.080 |
Why?
|
| Cytokines | 1 | 2014 | 1282 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2001 | 450 | 0.080 |
Why?
|
| Cell Survival | 1 | 2010 | 808 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 892 | 0.080 |
Why?
|
| Kinetics | 2 | 2002 | 1313 | 0.070 |
Why?
|
| Serotonin | 2 | 2000 | 232 | 0.070 |
Why?
|
| Antipyrine | 2 | 1999 | 4 | 0.070 |
Why?
|
| Carbon Radioisotopes | 2 | 1999 | 71 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2001 | 1008 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2005 | 94 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 752 | 0.070 |
Why?
|
| Ruthenium Red | 1 | 2006 | 3 | 0.070 |
Why?
|
| Action Potentials | 1 | 2010 | 501 | 0.070 |
Why?
|
| Manganese | 1 | 2006 | 47 | 0.070 |
Why?
|
| Brimonidine Tartrate | 2 | 1996 | 4 | 0.070 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 38 | 0.060 |
Why?
|
| DNA Primers | 1 | 2006 | 661 | 0.060 |
Why?
|
| Lipoxygenase | 1 | 2005 | 3 | 0.060 |
Why?
|
| Miconazole | 1 | 2005 | 5 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2006 | 269 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1608 | 0.060 |
Why?
|
| Species Specificity | 1 | 2006 | 548 | 0.060 |
Why?
|
| Hippocampus | 1 | 2010 | 820 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 92 | 0.060 |
Why?
|
| Amides | 1 | 2005 | 83 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2005 | 150 | 0.060 |
Why?
|
| Feedback | 1 | 2006 | 162 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 937 | 0.060 |
Why?
|
| Genotype | 1 | 2010 | 2535 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 341 | 0.060 |
Why?
|
| Muscle Tonus | 2 | 2002 | 7 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1292 | 0.050 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 2002 | 2 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 1114 | 0.050 |
Why?
|
| Antioxidants | 2 | 2005 | 338 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 66 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 1584 | 0.050 |
Why?
|
| Arachidonic Acids | 1 | 2002 | 19 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2023 | 118 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 90 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2002 | 223 | 0.050 |
Why?
|
| Humans | 6 | 2019 | 123072 | 0.050 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 2001 | 1 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2002 | 289 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 180 | 0.050 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2001 | 31 | 0.050 |
Why?
|
| Integrin beta3 | 1 | 2001 | 26 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2001 | 93 | 0.050 |
Why?
|
| Iloprost | 1 | 2001 | 10 | 0.050 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2001 | 8 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 2846 | 0.050 |
Why?
|
| Ouabain | 1 | 2000 | 27 | 0.050 |
Why?
|
| Hypertonic Solutions | 1 | 2000 | 20 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2001 | 118 | 0.050 |
Why?
|
| Sucrose | 1 | 2000 | 39 | 0.040 |
Why?
|
| Neurons | 1 | 2010 | 1935 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 174 | 0.040 |
Why?
|
| Gases | 1 | 2000 | 15 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4227 | 0.040 |
Why?
|
| Antibodies | 1 | 2001 | 370 | 0.040 |
Why?
|
| Tetraethylammonium | 1 | 1999 | 9 | 0.040 |
Why?
|
| Apamin | 1 | 1999 | 4 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2000 | 127 | 0.040 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 1999 | 12 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2001 | 421 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 1998 | 30 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2000 | 217 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2000 | 147 | 0.040 |
Why?
|
| KATP Channels | 1 | 1998 | 6 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1998 | 25 | 0.040 |
Why?
|
| Nitroarginine | 1 | 1998 | 11 | 0.040 |
Why?
|
| Cesium | 1 | 1998 | 13 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 479 | 0.040 |
Why?
|
| Functional Laterality | 1 | 1998 | 181 | 0.040 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 1997 | 2 | 0.040 |
Why?
|
| Thionucleosides | 1 | 1997 | 5 | 0.040 |
Why?
|
| Adenine Nucleotides | 1 | 1997 | 41 | 0.040 |
Why?
|
| Indazoles | 1 | 1997 | 23 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 697 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 747 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 187 | 0.030 |
Why?
|
| Idazoxan | 1 | 1996 | 2 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 128 | 0.030 |
Why?
|
| Dioxanes | 1 | 1996 | 4 | 0.030 |
Why?
|
| Adenosine | 1 | 1997 | 126 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 318 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2000 | 364 | 0.030 |
Why?
|
| Linear Models | 1 | 1998 | 669 | 0.030 |
Why?
|
| Iofetamine | 1 | 1995 | 1 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1995 | 22 | 0.030 |
Why?
|
| Amphetamines | 1 | 1995 | 10 | 0.030 |
Why?
|
| Autoradiography | 1 | 1995 | 71 | 0.030 |
Why?
|
| Peptides | 1 | 1999 | 794 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 171 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 1175 | 0.030 |
Why?
|
| Imidazoles | 1 | 1996 | 199 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 1995 | 55 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 43 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2014 | 151 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 360 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 427 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 348 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 1213 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 1660 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 455 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 586 | 0.020 |
Why?
|
| Pterins | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2005 | 14 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2005 | 32 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3316 | 0.020 |
Why?
|
| Homocysteine | 1 | 2005 | 121 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 382 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 256 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 617 | 0.010 |
Why?
|
| Partial Pressure | 1 | 2000 | 28 | 0.010 |
Why?
|
| Muscle Fatigue | 1 | 2000 | 7 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2000 | 42 | 0.010 |
Why?
|
| Chimera | 1 | 2000 | 88 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3042 | 0.010 |
Why?
|
| Diaphragm | 1 | 2000 | 99 | 0.010 |
Why?
|
| Heterozygote | 1 | 2000 | 672 | 0.010 |
Why?
|
| Oxygen | 1 | 2000 | 547 | 0.010 |
Why?
|
| Female | 2 | 2005 | 65534 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 5772 | 0.000 |
Why?
|